AACR Names T-Cell ALL Researcher as a 2023 Next Gen Star
By Anastasia Tikhonova, PhD - May 8, 2023Anastasia Tikhonova, PhD, was named a 2023 NextGen Star by the American Association for Cancer Research (AACR). Dr. Tikhonova, whose research is in T-cell acute lymphoblastic leukemia (ALL), talks about the honor of being awarded the title in this video interview.
Post Tags:AACR 2023
Advertisement
Related Posts
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.